Research & Development

Are New Cancer Treatments Bringing Hope to Patients with NSCLC?
Research & Development Are New Cancer Treatments Bringing Hope to Patients with NSCLC?

Recent advancements in cancer treatments have provided new hope for patients, with significant progress showcased in the biopharmaceutical industry. The interim results of ArriVent BioPharma, Inc.'s Phase 1b FURTHER trial for their drug firmonertinib have been particularly promising. This

September 13, 2024
How Will Cellares and Sony Transform Cell Therapy Manufacturing?
Research & Development How Will Cellares and Sony Transform Cell Therapy Manufacturing?

The world of cell therapy manufacturing is on the verge of a significant transformation. The partnership between Cellares, a leader in automated cell therapy manufacturing, and Sony Corporation, a technological giant renowned for its advanced flow cytometry, promises to reshape this burgeoning

September 12, 2024
Can Centessa's New Drug Revolutionize Sleep Disorder Treatments?
Research & Development Can Centessa's New Drug Revolutionize Sleep Disorder Treatments?

Sleep disorders are a growing public health concern, impacting millions of individuals worldwide. Addressing these disorders effectively has long been a challenge for pharmaceutical companies. Enter Centessa Pharmaceuticals, a London-based biotechnology company that has made headlines with its

September 11, 2024
Somite and OmniaBio Partner for AI-Driven DMD Cell Therapy Development
Research & Development Somite and OmniaBio Partner for AI-Driven DMD Cell Therapy Development

The recent partnership between Somite Therapeutics and OmniaBio Inc. marks a promising leap forward in treating Duchenne muscular dystrophy (DMD). Combining Somite's AI-driven approach with OmniaBio's cell and gene therapy expertise, this collaboration aims to expedite the development of

September 10, 2024
Sarepta Predicts Surging Elevidys Demand Despite Q2 Sales Dip
Research & Development Sarepta Predicts Surging Elevidys Demand Despite Q2 Sales Dip

Sarepta Therapeutics recently revealed financial results that indicate lower-than-expected sales for its flagship gene therapy product, Elevidys, designed to treat Duchenne muscular dystrophy (DMD). The sales figures for the second quarter fell short of Wall Street's projections, raising

September 9, 2024
Can T-cell Engagers Redefine Autoimmune Disease Treatments?
Research & Development Can T-cell Engagers Redefine Autoimmune Disease Treatments?

Autoimmune diseases, affecting millions of people worldwide, present a unique challenge where the body's immune system mistakenly attacks its tissues. Existing treatments primarily rely on immunosuppressants, which often come with severe side effects and don’t always offer a cure. Enter Candid

September 9, 2024
Loading

Subscribe to our weekly news digest!

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for subscribing.
We'll be sending you our best soon.
Something went wrong, please try again later